Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 8, 2006, Pages 1443-1450

  Einspahr, Janine G ^a,b   Martinez, Maria Elena ^b,c   Jiang, Ruiyun ^b   Hsu, Chiu Hsieh ^b,c   Bhattacharrya, Achyut K ^a   Ahnen, Dennis J ^e   Jacobs, Elizabeth T ^b,c   Houlihan, P Scott ^d   Webb, C Renee ^d   Alberts, David S ^a,b   Hamilton, Stanley R ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; ONCOPROTEIN; PROTEIN KI RAS; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL FEATURE; COLORECTAL ADENOMA; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOCARCINOMA; ADENOMA, VILLOUS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DEMOGRAPHY; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P53; GENES, RAS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION;

EID: 33748032054     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0144     Document Type: Article

References (75)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Morson B. President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Med 1974;67:451-7.
3. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28.
4. Fearon ER, Jones PA. Progressing toward a molecular description of colorectal cancer development. FASEB J 1992;6:2783-90.
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
6. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
7. Takayama T, Ohi M, Hayashi T, et al. Analysis of K-ras, APC, and β-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001;121:599-611.
8. Lamlum H, Papadopoulou A, Ilyas M, et al. APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci U S A 2000;97:2225-8.
9. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands Cohort Study. Carcinogenesis 2003;24:703-10.
10. Maltzman T, Knoll K, Martinez ME, et al. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology 2001;121:302-9.
11. Pricolo VE, Finkelstein SD, Wu TT, et al. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 1996;171:41-6.
12. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58:1149-58.
13. Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 1996;16:3839-44.
14. Kressner U, Bjorheim J, Westring S, et al. Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 1998;34:518-21.
15. Rashid A, Zahurak M, Goodman SN, Hamilton SR. Genetic epidemiology of mutated K-ras proto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas. Gut 1999;44:826-33.
16. McLellan EA, Owen RA, Stepniewska KA, Sheffield JP, Lemoine NR. High frequency of K-ras mutations in sporadic colorectal adenomas. Gut 1993;34:392-6.
17. Scott N, Bell SM, Sagar P, Blair GE, Dixon MF, Quirke P. p53 expression and K-ras mutation in colorectal adenomas. Gut 1993;34:621-4.
18. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
19. Hosaka S, Aoki Y, Akamatsu T, Nakamura N, Hosaka N, Kiyosawa K. Detection of genetic alterations in the p53 suppressor gene and the K-ras oncogene among different grades of dysplasia in patients with colorectal adenomas. Cancer 2002;94:219-27.
20. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-84.
21. Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002;99:9433-8.
22. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7.
23. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:255-71.
24. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer 1994;69:367-71.
25. Martinez-Garza SG, Nunez-Salazar A, Calderon-Garciduenas AL, Bosques-Padilla FJ, Niderhauser-Garcia A, Barrera-Saldana HA. Frequency and clinicopathology associations of K-ras mutations in colorectal cancer in a northeast Mexican population. Dig Dis 1999;17:225-9.
26. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
27. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:1193-7.
28. Zhu D, Keohavong P, Finkelstein SD, et al. K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res 1997;57:2485-92.
29. Hoffman M. Getting a handle on Ras activity. Science 1992;255:159.
30. Kikuchi-Yanoshita R, Konishi M, Ito S, et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 1992;52:3965-71.
31. Urosevic N, Krtolica K, Skaro-Milic A, Knezevic-Usaj S, Dujic A. Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 1993;54:249-54.
32. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85:692-6.
33. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
34. De Benedetti L, Varesco L, Pellegata NS, et al. Genetic events in sporadic colorectal adenomas: K-ras and p53 heterozygous mutations are not sufficient for malignant progression. Anticancer Res 1993;13:667-70.
35. Yamaguchi A, Makimoto K, Goi T, et al. Overexpression of p53 protein and proliferative activity in colorectal adenoma. Oncology 1994;51:224-7.
36. Kaklamanis L, Gatter KC, Mortensen N, et al. p53 expression in colorectal adenomas. Am J Pathol 1993;142:87-93.
37. van den Berg FM, Tigges AJ, Schipper ME, den Hartog-Jager FC, Kroes WG, Walboomers JM. Expression of the nuclear oncogene p53 in colon tumours. J Pathol 1989;157:193-9.
38. Rodrigues NR, Rowan A, Smith ME, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990;87:7555-9.
39. Campo E, de la Calle-Martin O, Miquel R, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 1991;51:4436-42.
40. Darmon E, Cleary KR, Wargovich MJ. Immunohistochemical analysis of p53 overexpression in human colonic tumors. Cancer Detect Prev 1994;18:187-95.
41. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156-62.
42. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
43. Martinez ME, Maltzman T, Marshall JR, et al. Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 1999;59:5181-5.
44. Nusko G, Sachse R, Mansmann U, Wittekind C, Hahn EG. K-RAS-2 gene mutations as predictors of metachronous colorectal adenomas. Scand J Gastroenterol 1997;32:1035-41.
45. Saraga E, Bautista D, Dorta G, et al. Genetic heterogeneity in sporadic colorectal adenomas. J Pathol 1997;181:281-6.
46. Norheim Andersen S, Breivik J, Lovig T, et al. K-ras mutations and HLA-DR expression in large bowel adenomas. Br J Cancer 1996;74:99-108.
47. Kobayashi M, Watanabe H, Ajioka Y, Honma T, Asakura H. Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers: relationship to distribution of proliferating cells. Hum Pathol 1996;27:1042-9.
48. Morris RG, Curb's LJ, Romanowski P, et al. Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa. J Pathol 1996;180:357-63.
49. Ajiki T, Fujimori T, Ikehara H, Saitoh Y, Maeda S. K-ras gene mutation related to histological atypias in human colorectal adenomas. Biotech Histochem 1995;70:90-4.
50. Arber N, Shapira I, Ratan J, et al. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology 2000;118:1045-50.
51. Ohnishi T, Tomita N, Monden T, et al. A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Br J Cancer 1997;75:341-7.
52. Ranaldi R, Gioacchini AM, Manzin A, Clementi M, Paolucci S, Bearzi I. Adenoma-carcinoma sequence of colorectum. Prevalence of K-ras gene mutation in adenomas with increasing degree of dysplasia and aneuploidy. Diagn Mol Pathol 1995;4:198-202.
53. Ohue M, Tomita N, Monden T, et al. A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res 1994;54:4798-804.
54. Yamagata S, Muto T, Uchida Y, et al. Lower incidence of K-ras codon 12 mutation in flat colorectal adenomas than in polypoid adenomas. Jpn J Cancer Res 1994;85:147-51.
55. Pignatelli M, Stamp GW, Kafiri G, Lane D, Bodmer WF. Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 1992;50:683-8.
56. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol 1991;138:807-13.
57. Nozaki R, Takagi K, Takano M, Miyata M. Clinical investigation of colorectal cancer detected by follow-up colonoscopy after endoscopic polypectomy. Dis Colon Rectum 1997;40:S16-22.
58. Ando M, Maruyama M, Oto M, Takemura K, Endo M, Yuasa Y. Higher frequency of point mutations in the c-K-ras 2 gene in human colorectal adenomas with severe atypia than in carcinomas. Jpn J Cancer Res 1991;82:245-9.
59. Slattery ML, Anderson K, Curtin K, et al. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res 2001;483:73-81.
60. Bouzourene H, Gervaz P, Cerottini JP, et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000;36:1008-15.
61. Yamagata S, Muto T, Uchida Y, et al. Polypoid growth and K-ras codon 12 mutation in colorectal cancer. Cancer 1995;75:953-7.
62. 6-alkylguanine. FASEB J 1992;6:2302-10.
63. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-8.
64. Beranek M, Bures J, Palicka V, Jandik P, Langr F, Nejedla E. A relationship between K-ras gene mutations and some clinical and histologic variables in patients with primary colorectal carcinoma. Clin Chem Lab Med 1999;37:723-7.
65. O'Brien H, Matthew JA, Gee JM, et al. K-ras mutations, rectal crypt cells proliferation, and meat consumption in patients with left-sided colorectal carcinoma. Eur J Cancer Prev 2000;9:41-7.
66. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001;81:1031-64.
67. Sugimura T. Nutrition and dietary carcinogens. Carcinogenesis 2000;21:387-95.
68. Saleh HA, Aburashed A, Bober P, Tabaczka P. P53 protein immunohistochemical expression in colonic adenomas with and without associated carcinoma. Am J Gastroenterol 1998;93:980-4.
69. Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52:1974-80.
70. Barletta A, Marzullo F, Pellecchia A, et al. DNA flow cytometry, p53 levels and proliferative cell nuclear antigen in human colon dysplastic, precancerous and cancerous tissues. Anticancer Res 1998;18:1677-82.
71. Kawasaki Y, Monden T, Morimoto H, et al. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 1992;97:244-9.
72. Hasegawa H, Ueda M, Furukawa K, et al. p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence. Int J Cancer 1995;64:47-51.
73. Slattery ML, Curtin K, Schaffer D, Anderson K, Samowitz W. Associations between family history of colorectal cancer and genetic alterations in tumors. Int J Cancer 2002;97:823-7.
74. Freedman AN, Michalek AM, Marshall JR, et al. Familial and nutritional risk factors for p53 overexpression in colorectal cancer. Cancer Epidemiol Biomarkers Prev 1996;5:285-91.
75. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.